|
11 Dec 2019 |
BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders
|
|
11 Dec 2019 |
Seattle Genetics Announces Positive Tucatinib HER2CLIMB Trial Results in Locally Advanced or Metastatic HER2-Positive Breast Cancer Presented at 2019 SABCS and Published in the New England Journal of Medicine
|
|
11 Dec 2019 |
BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
|
|
11 Dec 2019 |
Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer
|
|
11 Dec 2019 |
EicOsis Announces First Subject Dosed in Phase 1a Clinical Trial of EC5026
|
|
10 Dec 2019 |
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene
|
|
10 Dec 2019 |
Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001
|
|
10 Dec 2019 |
Daiichi Sankyo Initiates Pivotal Phase 2 Trial in Japan with Valemetostat in Patients with Adult T-Cell Leukemia-Lymphoma
|
|
10 Dec 2019 |
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
|
|
10 Dec 2019 |
Kymera Therapeutics to Present Preclinical Data Demonstrating Potent Antitumor Activity by a Selective STAT3 Degrader in Hematologic Malignancies at the American Society of Hematology Annual Meeting
|
|
10 Dec 2019 |
Astex Pharmaceuticals Presents Topline Data from the ASCERTAIN Phase 3 Study of its Novel, Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.
|
|
10 Dec 2019 |
KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema
|
|
10 Dec 2019 |
Jasper Therapeutics Announces Upcoming Data Presentation on Lead Program, JSP191, at 61st American Society of Hematology (ASH) Annual Meeting & Exposition
|
|
09 Dec 2019 |
FORMA Therapeutics Announces Clinical Data for Sickle Cell Disease Candidate FT-4202, Demonstrating Multi-modal Activity of PKR Activation Increases Oxygen Affinity and Decreases Sickle Hemoglobin Polymerization, at 61st Annual ASH Meeting
|
|
09 Dec 2019 |
FORMA Therapeutics Announces Positive Preliminary Phase 1/2 IDH1m Inhibitor Olutasidenib Results Demonstrating Rapid Clinical Remissions and Mutation Clearance in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
|
09 Dec 2019 |
Seven and Eight BioPharmaceuticals, Inc. Announces Clinical Collaboration to Evaluate BDB001 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
|
|
09 Dec 2019 |
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
|
|
09 Dec 2019 |
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
|
|
09 Dec 2019 |
61st ASH Congress 2019: Menarini Ricerche presents the latest updates about the First In Human clinical trial of SEL24/MEN1703
|
|
09 Dec 2019 |
Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting
|
|
09 Dec 2019 |
Moberg Pharma Meets Primary Endpoint for MOB-015 in a Phase 3 Study for the Treatment of Onychomycosis
|
|
09 Dec 2019 |
Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy
|
|
09 Dec 2019 |
Algiax Is Ready to Go Into Proof-of-Concept for AP-325 and Welcomes New Investors
|
|
09 Dec 2019 |
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
|
|
08 Dec 2019 |
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
|
